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 29 
ABSTRACT 30 
One hundred twenty Burkholderia cepacia complex isolates collected during 2004–2010 31 
from 66 patients in two cystic fibrosis reference centers in Argentina were analyzed. B. 32 
contaminans was the species most frequently recovered (57.6%) followed by B. 33 
cenocepacia (15%), a species distribution not reported so far. The recA-PCR-based 34 
techniques applied to the B. contaminans isolates revealed that 85% of the population 35 
carried the recA-ST-71 allele. Our results showed the utility of BOX-PCR genotyping in 36 
analyzing B. contaminans diversity. This approach allowed us to address a clonal 37 
transmission during an outbreak and the genetic changes occurring in infecting bacteria 38 
over the course of chronic infection. 39 
40 
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 41 
  Burkholderia cepacia complex species are capable of causing chronic and often severe 42 
respiratory-tract infections in cystic fibrosis (CF) patients and other types of infections in 43 
immunocompromised patients. Although many CF patients remain infected by these 44 
bacteria and relatively healthy for prolonged periods, others either have a severe decline in 45 
their pulmonary status, or die shortly after the initial colonization (2). In Argentina, the 46 
first reports of B. cepacia complex bacteria infecting CF patients started around 1990. At 47 
that time Burkholderia spp. were recovered sporadically and with a very low prevalence 48 
(<0.1%). The prevalence started to increase over the last decade from 0.2 to 3.6% 49 
depending on the medical center. In early 2004 an outbreak involving main Argentine CF-50 
care centers occurred, and the proportion of patients from whom B. cepacia complex 51 
species could be recovered ranged from 19 to 36% (5, 18, 22). Currently, through strict 52 
infection-control procedures, the prevalence of Burkholderia spp. in local patients has 53 
decreased to approximately 10%. Recent worldwide surveillance studies concerning the 54 
distribution of B. cepacia complex species in CF patients have cited as the most frequently 55 
recovered species B. multivorans and B. cenocepacia. These species account for 56 
approximately 80% of the infected patients, and the prevalence between them is 57 
geographically and temporally dependent (13, 15, 19). Unlike this worldwide situation, in 58 
Argentina a relatively high prevalence of B. contaminans followed by B. cenocepacia has 59 
been encountered (18, 22). To our knowledge, no other geographical region has been 60 
reported in the literature with such a high occurrence of B. contaminans infecting CF 61 
patients. In view of this particular scenario coupled with the lack of biodiversity 62 
information available for B. contaminans species, we decided to study this local 63 
population by recA-PCR-based techniques and by repetitive element sequence-based PCR 64 
(rep-PCR) approaches. These methods allowed us to address the genetic diversity of B. 65 
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contaminans isolates recovered during that outbreak along with the genetic changes 66 
occurring in the infecting bacteria over the course of a chronic infection. 67 
  Distribution of Burkholderia cepacia complex species in CF patients. This study 68 
involved the analysis of a total of 120 clinical Burkholderia cepacia complex isolates 69 
recovered from 66 CF patients from 2004 through 2010 and 13 reference strains (Table 70 
S1, Supplementary Material). The isolates were recovered from sputum samples of CF 71 
patients treated at 2 main CF reference centers of Argentina (Hospital de Niños Sor María 72 
Ludovica, La Plata [HNLP], and Hospital Santísima Trinidad, Córdoba [HST], located 73 
800 km from La Plata to the north; plus one hospital (Hospital Dr. Pedro Moguillanski, 74 
Cipoletti, Río Negro [HNRN], 1,200 km from La Plata to the south. Twenty-two isolates 75 
(indicated with a “v” in Table S1, Supplementary Material) were withdrawn from patients 76 
infected during the B. cepacia complex outbreak, and a cohort of 51 isolates was 77 
recovered from 21 patients chronically infected with B. cepacia complex bacteria. Patients 78 
were considered chronically infected when three positive cultures of B. cepacia complex 79 
strains were isolated within a 6-month period (24). Bacterial isolation was performed on 80 
B. cepacia selective agar medium (BCSA, Lab. Britania S. A., Argentina) according to 81 
clinical microbiology practice recommendations for respiratory-tract specimens from CF 82 
patients (9, 16) and were phenotypically characterized by means of conventional 83 
biochemical techniques (9, 16, 23, 33). The species-level identification was achieved by 84 
recA-PCR-based techniques. The recA gene (1040 bp) was amplified through the use of 85 
BCR1 and BCR2 primers (21) and the amplified products subjected to restriction-86 
fragment-length-polymorphism (RFLP) analysis with the restriction enzyme HaeIII 87 
(Promega, Inc.; 21). The restriction-PCR patterns obtained were analyzed and compared 88 
with those reported in the literature (11, 12, 21, 29). The amplified products were purified 89 
through the use of the QIAquick PCR-purification kit (Qiagen Inc., CA, USA), and 90 
sequenced on both strands with the BigDye Terminator Cycle Sequencing Ready Reaction 91 
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kit (Applied Biosystem, Foster City, CA, USA) at Macrogen, Inc. (Seoul, Korea). A final 92 
identification was achieved by recA-gene-DNA-sequence analysis and gyrB DNA 93 
fragment (1,900 bp) sequencing when an identification remained ambiguous. The recA-94 
sequence type (recA-ST) within each species was obtained by comparing the sequence of 95 
a 398 bp recA fragment against the Multi Locus Sequence Typing (MLST) database 96 
(http://pubmlst.org/bcc/) (2). 97 
  The analysis of species distribution among the patients studied showed that 8 out of the 98 
17 species described for the B. cepacia complex were infecting the local CF population, 99 
with a remarkably high representation of B. contaminans that accounted for 57.6% of the 100 
infected patients. The data on the species of the first isolate available from each patient 101 
indicated that B. cenocepacia was the second most frequent species, it encountered at a 102 
frequency of almost 15% of the patients, followed by B. cepacia at 7.5%, B. multivorans 103 
at 6.0%, B. stabilis and B. vietnamiensis at 5%, B. seminalis at 3.0 %, and B. ambifaria at 104 
1.5%. 105 
  In order to examine the genetic diversity among the B. contaminans isolates, sequence 106 
analysis of a 900 bp fragment of the recA gene was performed over the 79 B. contaminans 107 
isolates (Table S1, Supplementary Material). The phylogenetic relationship among them 108 
was investigated through the use of the MEGA version 4.0 software 109 
(http://www.megasoftware.net; Fig. 1). Isolates were clearly separated into one large 110 
homogenous cluster that grouped 85% of the B. contaminans population under study along 111 
with four small clusters containing only 5 isolates. When the sequence of the 398 bp DNA 112 
fragment from the recA gene was compared against the MLST database (2), all the 113 
bacteria included in the main cluster showed to belong to the recA-ST-71 allele; while 4 of 114 
the isolates grouping outside this cluster displayed different recA-ST alleles (ST-64, -166, 115 
and -243). The isolates grouped in the main cluster had a recA-HaeIII-restriction pattern 116 
corresponding to the K-type, whereas the isolates outside this group gave profiles of K, 117 
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AT, and J (Table S1, Supplementary Material). Interestingly, one of the isolates (HNLP 118 
1001) exhibited the J recA-RFLP pattern which was reported to be representative of the 119 
species B. cenocepacia, B. stabilis, B. lata, B. seminalis, and B. arboris (21,27, 28), but so 120 
far not documented for B. contaminans. It is notable that none of the recA sequences 121 
corresponding to isolates that grouped in the main cluster was represented by the recA 122 
reference sequences available at GenBank. It should also be remarked that two reference 123 
sequences displaying the recA-ST-71 allele, those belonging to two isolates recovered 124 
from CF patients in Brazil (B. contaminans R18428 and R9929), clustered at a short 125 
distance from the homogenous cluster (Fig. 1). A further exploration of a possible regional 126 
incidence of B. contaminans among isolates circulating in Brazil should prove interesting. 127 
In this regard, the incidence of RFLP K pattern strains in CF patients seen at two different 128 
hospitals in Brazil (1, 12) might also be indicating the existence of a regional spreading of 129 
B. contaminans between bordering countries. 130 
  Genetic diversity among B. contaminans isolates with the recA–ST-71 allele as 131 
investigated by Rep-PCR DNA fingerprinting analysis. The low level of polymorphism 132 
in the recA gene encountered in the B. contaminans population studied here prompted us 133 
to explore the genetic diversity among the isolates carrying the recA-ST-71 allele by 134 
repetitive element sequence-based PCR (rep-PCR; 30). This subset of 75 B. contaminans 135 
isolates was analyzed by REP-, ERIC- and BOX-PCRs. Amplification reactions were 136 
performed in a My Cycler Thermal Cycler (BIO-RAD, USA) with the REP1R-I, REP2-I, 137 
ERIC1R-I, and BOX-A1R primers (30). The amplicons generated were electrophoresed in 138 
agarose gels and the banding patterns obtained analyzed by means of the GelCompar II 139 
version 2.1 software package (Applied Maths, Kortrijk, Belgium). The profiles yielding a 140 
band similarity of 85% or greater were considered related clones for all assays. According 141 
to this criterion, both REP- and ERIC-banding patterns displayed a very limited diversity. 142 
With the REP primers, the isolates showed only four different banding patterns, with one 143 
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being observed in 92% of the isolates. Similarly, when ERIC-PCR primers were used, 5 144 
different patterns were found, with one subtype including 89% of the isolates (data not 145 
shown). The highest discrimination power was obtained when BOX-PCR was performed. 146 
This fingerprint typing yielded 10 distinct amplification profiles (B1 to B10; Fig. 2). The 147 
distribution of the isolates' amplification profiles was as follows: the B8 subtype, 50%; the 148 
B1 subtype, 22.9%; the B6 and B7 subtypes, 6.75%; the B9 subtype, 5.4%; and the B2, 149 
B3, B7, B5, and B10 subtypes, 1.35%, these comprising only 1 isolate each. 150 
  Through the use of the first B. contaminans isolate recovered from each patient over the 151 
period 2004–2010, the incidence of each BOX subtype was determined. Three subtypes, 152 
B1, B7, and B8 were the most abundant patterns found, all together accounting for 75% of 153 
the isolates. The B6 subtype was observed in 3 patients, while the remaining 6 subtypes 154 
were unique fingerprints observed in only one patient each (Fig. 3A). With respect to the 155 
geographical distribution, whereas the isolates with B7 and B8 subtypes were found at 156 
both references centers at a remarkably high incidence, all the other BOX subtypes were 157 
present at only one of the two locations (Fig. 3B). Thus, although the interpatient 158 
transmission of B. contaminans with the B7 and B8 BOX subtypes could very likely have 159 
been a dominant occurrence at both CF centers, other sources of new infections were 160 
clearly present. Regarding the prevalence of each BOX subtype over time, during the 161 
period of the outbreak ( 2004–2005), the CF patients were in most instances infected with 162 
the B8 (55%), B7 (15%), and B6 (11%) subtypes—but also in a much lower proportion 163 
with isolates belonging to other genotypes (B2, B3, B4, B9, and B10; Fig. 3C). We 164 
therefore infer that the isolates belonging to the B8 genotype (and to a lesser extent to B7), 165 
were efficiently transmitted at the outbreak period to produce a clonal spreading among 166 
the patients (Fig. 3B and 3C). Nevertheless, that other different unique BOX subtypes (e. 167 
g., the B2, B3, B4, B9, and B10 subtypes) were also present should be stressed (Fig. 3C). 168 
Hence, as previously reported for different Burkholderia spp. outbreaks (4), although a 169 
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high number of infections could have been the result of particular BOX subtype patient 170 
transmission, other sources of infection—such as through the environment or industrial 171 
products—might have accounted for the CF infections within that same time period. 172 
Additionally, it should be noted that since 2005 onward, isolates belonging to BOX 173 
subtypes B1 and B8 most notably seem to be responsible for new infections in CF 174 
patients. The PCR-fingerprinting techniques have been successfully applied previously for 175 
B. cenocepacia, B. cepacia, B. multivorans, B. dolosa, and B. pseudomallei clinical-isolate 176 
discrimination (4, 8). In fact, the application of ERIC- and BOX-PCR have proven to be 177 
valid technical alternatives to pulsed-field gel electrophoresis (6, 8, 10). In the present 178 
work, we were able to demonstrate that BOX-PCR is also a reliable typing method to 179 
examine the genetic relatedness among B. contaminans isolates so as to enable the 180 
identification of a spreading of two different genotypes within a very closely related group 181 
of isolates. 182 
  B. contaminans diversity in chronically infected patients. CF patients are known to be 183 
susceptible to respiratory-tract chronic infection by certain Burkholderia species (3). Both 184 
the persistence of the same strain and the colonization with a different strain during the 185 
course of long-term infection have been reported (3, 7, 20). In 8 out of the 21 chronically 186 
infected patients analyzed in this work during the 7-year period, more than one 187 
Burkholderia species was recovered during the course of the infection (Table 1, rows 1 to 188 
3), either as a consequence of coinfection or through subsequent colonization by different 189 
species (so-called “species replacement”). In contrast, in the remaining 13 chronically 190 
infected patients only one species (B. contaminans) was obtained (Table 1, rows 4 and 5). 191 
Upon consideration of the BOX subtypes of serially recovered isolates during the infection 192 
of each of these 13 patients we found that 5 patients remained infected with isolates 193 
carrying the same BOX subtype, whereas the other 8 evidenced a change in their isolate’s 194 
BOX subtype during chronic infection. The latter result again could have occurred either 195 
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as a consequence of a “strain replacement” or through coinfection with different isolates 196 
being collected—completely by chance—at the different samplings (31). In addition, the 197 
BOX-PCR diversity among the isolates recovered throughout the course of prolonged 198 
infection demonstrated that those clones isolated during the first year or years of infection 199 
belonged to different BOX subtypes (B6–B8) with the B8 subtype being predominant—200 
that finding probably since the sample collection overlapped with the outbreak period 201 
(2004–2005). In contrast, after a long-lasting infection (more then three years of being 202 
colonized by B. contaminans), either the B1 or B8 BOX subtypes became predominant, 203 
and were likely coexistent (31). Therefore, we conclude that the BOX-subtype diversity of 204 
the infecting strains responsible for the chronic cases investigated seemed to decrease over 205 
the time of infection, with B1 and B8 subtypes being the ones that mostly persisted—and 206 
apparently replacing the initially infecting strains. This type of occurrence was found to be 207 
common in P. aeruginosa infections; where after a period of recurrent colonization, the 208 
CF patients became colonized permanently with a single lineage (17, 25). Once this P. 209 
aeruginosa lineage became adapted to the hostile environment of the CF lung (i. e., as the 210 
“adapted dominant epidemic strain”), that bacterium could persist for several decades so 211 
as to overcome both the host defense mechanisms and any intensive antibiotic therapy (14, 212 
17, 26, 32).  213 
  In conclusion, the species B. contaminans was indeed able to develop chronic 214 
colonization in CF patients. Especially isolates belonging to the B8 and B1 BOX subtypes 215 
persisted during the 7 years of our surveillance, either infecting CF patients for the first 216 
time (Fig. 3C) or colonizing CF patients chronically. We therefore can infer that the 217 
aforementioned genotypes can survive in certain ecological niches or industrial products, 218 
spread among patients, and most readily adapt to the lungs of CF patients. This research 219 
has enabled a deeper understanding of the diversity of the B. contaminans isolates 220 
recovered from CF patients treated in Argentina. Since a knowledge of the currently 221 
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infectious strains is critical in prescribing patient treatment and making prognoses, isolates 222 
characterized by the B1 and B8 subtypes have now become the object of ongoing 223 
investigations in our laboratory. This and the forthcoming information will provide deeper 224 
insights into the strategies employed by B. contaminans to adapt and persist within CF 225 
patients. 226 
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Table 1. Burkholderia cepacia complex species recovered from 21 patients over the time 236 
period of their chronic infections. 237 
 238 
Burkholderia cepacia complex 
species recovered from the 
initial sample a 
Species recovered in 
subsequent samples 
Number of 
patients 
B. contaminans B. cenocepacia 4 
B. cepacia B. vietnamiensis 2 
B. cenocepacia B. contaminans, B. cenocepacia 2b 
B. contaminans B. contaminans 5c 
B. contaminans  B. contaminans 8d 
 239 
a Identification of the first available clinical isolates recovered from the chronic patients. 240 
b Species different from the initial one was detected and then, in later cultures, the initial 241 
species was found again, indicating probable species co-infection. 242 
c The same BOX-subtype was detected in subsequent cultures. 243 
d Different BOX subtype patterns were detected in subsequent sputum cultures.  244 
245 
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 246 
LEGENDS TO THE FIGURES 247 
 248 
Fig. 1. Phylogenetic tree of the 79 B. contaminans CF isolates (Table S1 in Supplementary 249 
Material) based on the analysis of a 900 bp recA fragment sequence using the neighbor-250 
joining method. Bootstrap values greater than 70% are shown for 1,500 replicates. Five B. 251 
contaminans reference sequences obtained from the GenBank sequence database were 252 
included in the analysis (ascension numbers indicated in brackets). RecA-gene-sequence 253 
types (recA-STs) were obtained by comparing the sequence of a 398 bp recA fragment 254 
against the public MLST database (http://pubmlst.org/bcc/). B. xenovorans was used as 255 
the outgroup.  256 
 257 
 258 
Fig. 2. Dendrogram showing the relatedness among representative BOX-PCR 259 
fingerprinting patterns obtained from Burkholderia contaminans recA-ST-71 clinical 260 
isolates. The dendrogram was produced by the UPGMA method. The scale bars indicate 261 
the percent similarity. Clusters were delineated with an 85%-similarity cut-off value as 262 
indicated by the heavy vertical line. One isolate representative of each pattern is indicated. 263 
For the key to the abbreviations used for the medical centers, cf. the text. 264 
 265 
Fig. 3. Distribution of BOX-PCR subtypes (B1–B10) of B. contaminans isolates with the 266 
recA-ST-71 allele obtained over a 7-year period with only the first isolate recovered from 267 
each patient being considered: A) Incidence; B) Geographical distribution; C) Temporal 268 
distribution. 269 
 270 
271 
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